C-peptide is a bioactive
peptide with a potentially protective role in
diabetes complications; however, its molecular mechanism of protection against cardiovascular damage caused by
hyperglycemia-induced apoptosis remains unclear. We investigated the protective mechanism of
C-peptide against
hyperglycemia-induced apoptosis using human umbilical vein endothelial cells and
streptozotocin diabetic mice. High
glucose (33 mmol/L) induced apoptotic cell death in endothelial cells via sequential elevation of intracellular Ca(2+) and
reactive oxygen species (ROS) as well as subsequent activation of
transglutaminase 2 (TG2).
C-peptide (1 nmol/L) prevented endothelial cell death by inhibiting
protein kinase C- and
NADPH oxidase-dependent intracellular ROS generation and by abolishing high
glucose-induced TG2 activation, without affecting intracellular Ca(2+) levels. Consistently, in the aorta of
streptozotocin diabetic mice,
hyperglycemia stimulated transamidating activity and endothelial cell apoptosis that was inhibited by
C-peptide replacement
therapy (35 pmol/min/kg) using osmotic pumps (control and diabetes, n = 8; diabetes +
C-peptide, n = 7). In addition,
C-peptide prevented
hyperglycemia-induced activation of transamidation activity and apoptosis in the heart and renal cortex of
streptozotocin diabetic mice. Thus,
C-peptide protects endothelial cells from
hyperglycemia-induced apoptotic cell death by inhibiting intracellular ROS-mediated activation of TG2. Furthermore, TG2 may be a promising avenue of therapeutic investigation to treat diabetic vasculopathies.